Interleukin-8 produced from cancer-associated fibroblasts suppresses proliferation of the OCUCh-LM1 cancer cell line

Table 2 Clinicopathological characteristics of 154 patients with BTCs

		number
Sex	men	86
Sex	women	68
Age, median (range)		69 (43–87)
Differentiated	differentiated	123
	undifferentiated	14
	other	17
Location of cancer	peripheral and distal bile duct	67
	intrahepatic bile duct	24
	gallbladder	27
	ampullary	36
T category	pT0	19
	pT1	21
	pT2	49
	pT3	58
	pT4	7
Lymph node metastasis	absent	98
Lymph node metastasis	present	49
Distant metastasis	absent	136
Distant metastasis	present	11
Lymphatic invasion	absent	60
Lymphatic invasion	present	64
Vascular invasion	absent	21
Vascular invasion	present	103
Neural invasion	absent	58
Neural invasion	present	62
UICC stage	0	19
	1	23
	2	66
	3	42
	4	4
Serum CEA level, ng/ml, median (range)		2.6 (0–86.5)
Serum CA19–9 level, U/ml, median (range)		29 (0–45,152)
Recurrence	yes	76
Recurrence	no	78
Outcome	death	70
Outcome	alive	84
Recurrence free survival, days, median (range)		521 (0–4160)
Overall survival, days, median (range)		778 (9–4157)

BTCs bile tract cancers, UICC Union for International Cancer Control, CEA carcinoembryonic antigen, CA19–9; carbohydrate antigen 19–9

ISSN: 1471-2407